Almanack Investment Partners LLC. Acquires 3,456 Shares of Johnson & Johnson $JNJ

Almanack Investment Partners LLC. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 52.1% during the second quarter, HoldingsChannel reports. The fund owned 10,089 shares of the company’s stock after purchasing an additional 3,456 shares during the quarter. Almanack Investment Partners LLC.’s holdings in Johnson & Johnson were worth $1,541,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Highline Wealth Partners LLC boosted its stake in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $48,000. Finally, von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $49,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. HSBC increased their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Citigroup increased their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Finally, Morgan Stanley increased their target price on shares of Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $193.88.

Johnson & Johnson Stock Performance

JNJ opened at $190.88 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company’s fifty day moving average price is $179.28 and its two-hundred day moving average price is $164.16. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a market cap of $459.70 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $24.02 billion for the quarter. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.